Needham & Company LLC Reaffirms “Hold” Rating for STERIS (NYSE:STE)

STERIS (NYSE:STE)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a research note issued on Monday,Benzinga reports.

STE has been the subject of several other research reports. JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Thursday, February 6th. Piper Sandler boosted their price target on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Stephens restated an “overweight” rating and issued a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $258.75.

STERIS Stock Performance

Shares of STE stock opened at $208.26 on Monday. The company has a market cap of $20.46 billion, a P/E ratio of 44.22 and a beta of 0.87. The firm has a fifty day moving average price of $222.54 and a 200 day moving average price of $219.97. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS has a 12 month low of $197.82 and a 12 month high of $248.24.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Sell-side analysts predict that STERIS will post 9.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Avalon Trust Co acquired a new stake in shares of STERIS during the fourth quarter worth about $30,000. Human Investing LLC purchased a new stake in STERIS during the 4th quarter valued at approximately $31,000. Anfield Capital Management LLC lifted its position in STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division lifted its position in STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 76 shares during the period. Finally, Manchester Capital Management LLC increased its holdings in shares of STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 137 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.